

# Angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis prevents pancreatic acinar cell inflammatory response via inhibition of the p38 mitogen-activated protein kinase/nuclear factor- $\kappa$ B pathway

XIAOZHENG YU<sup>1\*</sup>, LIJIAN CUI<sup>2\*</sup>, FEI HOU<sup>3</sup>, XIAOYA LIU<sup>1</sup>, YAN WANG<sup>3</sup>, YAN WEN<sup>3</sup>,  
CHENG CHI<sup>1</sup>, CHUNYUN LI<sup>1</sup>, RUIXIA LIU<sup>4</sup> and CHENGHONG YIN<sup>1</sup>

<sup>1</sup>Department of Internal Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026;

<sup>2</sup>Department of Emergency, Beijing Chaoyang Hospital (Jingxi Campus), Capital Medical University, Beijing 100043;

<sup>3</sup>Department of Infectious Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050;

<sup>4</sup>Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, P.R. China

Received January 17, 2017; Accepted November 7, 2017

DOI: 10.3892/ijmm.2017.3252

**Abstract.** The aim of the present study was to investigate the role of the angiotensin-converting enzyme (ACE)2-angiotensin-(Ang)-(1-7)-Mas axis in the pathogenesis of pancreatitis and the association between this axis and the p38 mitogen-activated protein kinase (p38 MAPK)/nuclear factor (NF- $\kappa$ B) signaling pathway in pancreatic acinar cells. Mouse pancreatic acinar cancer (MPC-83) cells were stimulated with 10 nM caerulein (CAE) to create an *in vitro* model of acute pancreatitis, and collected for analysis at 2, 6, 12, 24 and 48 h post stimulation. In addition, cells were pretreated with different concentrations of Ang-(1-7), Ang-(1-7) antagonist A779, p38 MAPK inhibitor SB203580 or ACE2 inhibitor DX600 for 30 min, and then stimulated with CAE for 24 h. The ACE2, Mas receptor, p38 MAPK, phosphorylated (p)-p38 MAPK and NF- $\kappa$ B expression levels were evaluated using western blotting and immunofluorescence. p38 MAPK, NF- $\kappa$ B, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-6 (IL-6), IL-8 and IL-10 mRNA expression levels were assessed using reverse transcription-quantitative polymerase chain reaction.

The results of the immunofluorescence assay demonstrated that ACE2 and p38 MAPK were present mainly in the cytoplasm, while the Mas receptor was located mainly in the cell membrane. ACE2, p38 MAPK and p-p38 MAPK protein levels were significantly increased ( $P < 0.05$ ) following stimulation with CAE compared with those in the control group and peaked at 24 h. Mas receptor protein levels were significantly upregulated ( $P < 0.05$ ) between 6 and 24 h, peaking at 12 h. Ang-(1-7) and SB203580 downregulated p-p38 MAPK and NF- $\kappa$ B expression and the mRNA levels of inflammatory factors IL-6, TNF- $\alpha$  and IL-8, but upregulated the mRNA level of inflammatory factor IL-10 compared with those treated with CAE alone. These results were supported by the opposite outcomes observed for cells treated with A779 or DX600. Therefore, it was concluded that the ACE2-Ang-(1-7)-Mas axis significantly inhibits pancreatitis by inhibition of the p38 MAPK/NF- $\kappa$ B signaling pathway.

## Introduction

Acute pancreatitis (AP) is one of the most catastrophic upper abdominal disorders (1,2). AP is characterized by auto-digestion of the pancreas following intra-acinar zymogen activation and the release of pancreatic activated enzymes, which causes acinar cell injury, systemic inflammatory response syndrome and even persistent multiple organ failure (3-5). Approximately 20% of cases of AP are associated with multi-organ dysfunction and local complications, and patients with persistent organ failure within the first few days are at an increased risk of succumbing to the disease, with a mortality rate approaching 30% (2). In addition, the development of infected necrosis among patients with severe acute pancreatitis (SAP) is associated with extremely high mortality (6-8).

The renin-angiotensin (Ang) system (RAS) is important in the maintenance of cardiovascular homeostasis, fluid and salt balance, and has been implicated to play a role in diabetes, chronic renal disease and hepatic fibrosis (9-11). Increased activity of the arm of the RAS comprising Ang-converting

*Correspondence to:* Dr Chenghong Yin, Department of Internal Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 251 Yaojiayuan Road, Chaoyang, Beijing 100026, P.R. China  
E-mail: modscn@126.com

Dr Ruixia Liu, Department of Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 251 Yaojiayuan Road, Chaoyang, Beijing 100026, P.R. China  
E-mail: liuruixia1982@163.com

\*Contributed equally

**Key words:** angiotensin-converting enzyme 2, angiotensin-(1-7), pancreatic acinar cells, p38 mitogen-activated protein kinase

enzyme (ACE), AngII and AngII receptor 1 (AT1), namely the ACE-AngII-AT1 axis, may aggravate the development of pancreatitis (12-14). However, ACE2, Ang-(1-7) and the Ang-(1-7) receptor Mas constitute another arm of the RAS, the ACE2-Ang-(1-7)-Mas axis, which may counteract the ACE-AngII-AT1 axis (15,16). ACE2 cleaves AngII into the vasodilatory peptide Ang-(1-7), which has certain functions opposing those of AngII; AngII promotes vasoconstriction, cell proliferation, pro-thrombotic activity and inflammation, whereas Ang-(1-7) has vasodilatory, anti-proliferative, anti-thrombotic and anti-inflammatory functions (17-19). Thus, Ang-(1-7) is considered an important active product in the pathophysiology of numerous diseases, such as heart failure, diabetes, disuse-induced skeletal muscle atrophy and microcirculation (20-24). The manufacture and use of the Ang-(1-7)-specific receptor (Mas) antagonist, D-Ala-7-Ang-(1-7), also known as A779, has allowed further analysis of the Mas receptor for Ang-(1-7). Oruc *et al* (25) demonstrated that the activation of the RAS is closely associated with AP. In addition, previous studies conducted by the present research group have shown that SAP is associated with upregulation of the ACE2-Ang-(1-7)-Mas axis and promotes increased circulating levels of Ang-(1-7) (26-28). However, whether the ACE2-Ang-(1-7)-Mas axis serves a protective role in the pathogenesis of pancreatitis, and the signaling pathway through which the ACE2-Ang-(1-7)-Mas axis protects pancreatic cells from inflammation remain unknown. The p38-mitogen-activated protein kinase (p38 MAPK), a member of the MAPK family, is considered to be an important kinase in stress signalling (29). The p38 MAPK signaling transduction pathway plays an essential role in the regulation of a number of cellular processes, including inflammation, cell cycling, cell differentiation, cell growth and cell death (30,31). MAPK activation initiates the downstream induction of nuclear factor- $\kappa$ B (NF- $\kappa$ B), which is an essential regulator of the expression of numerous genes involved in the function and development of the immune system and in inflammatory responses (32-34). There is also evidence to indicate that p38 MAPK is involved in the activation of pro-inflammatory nuclear transcription factors such as NF- $\kappa$ B in isolated pancreatic acinar cells (35); p38 MAPK has been demonstrated to regulate NF- $\kappa$ B pathway activation in AR42J cells (36). These findings indicate that the p38 MAPK/NF- $\kappa$ B signaling pathway potentially serves a role in the pathogenesis of AP. Thus, the aforementioned studies suggest the possibility that the ACE2-Ang-(1-7)-Mas axis protects pancreatic acinar cells from damage via the p38 MAPK/NF- $\kappa$ B signaling pathway.

The present study was conducted to investigate the hypothesis that the ACE2-Ang-(1-7)-Mas axis protects pancreatic cells from damage through the p38 MAPK/NF- $\kappa$ B signaling pathway. The aim of the study was to examine the effect of the ACE2-Ang-(1-7)-Mas axis on caerulein (CAE)-stimulated MPC-83 cells, and to identify whether this axis contributes to the pathogenesis of pancreatitis through the p38 MAPK/NF- $\kappa$ B pathway in acinar cells.

## Materials and methods

**Cell culture and treatments.** MPC-83 mouse pancreatic acinar cancer cells (Cancer Institute and Hospital, Chinese Academy

of Medical Sciences, Beijing, China) were cultured in RPMI-1640 medium (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 mg/ml streptomycin. The cells were incubated at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. All experiments were carried out 24 h after the cells were seeded.

The cells were stimulated with 10 nmol/l (M) CAE (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for various time periods to create a model of AP (37). CAE is a functional analog of cholecystokinin that causes exocrine secretion and an inflammatory response in pancreatic cells (38). Generally, 10 nM CAE is used to induce the inflammation of pancreatic acinar cells as a model of AP (39). The cells were divided into six groups: Control, CAE (AP), CAE + Ang-(1-7), CAE + A779, SB203580 and DX600 groups. The control group comprised normally growing MPC-83 cells without stimulation. In the CAE group, MPC-83 cells were stimulated with 10 nM CAE for 2, 6, 12, 24 or 48 h. In the CAE + Ang-(1-7), CAE + A779, SB203580 and DX600 groups, a 24 h time period for stimulation with CAE was chosen on the basis of preliminary experiments (data not shown). Our preliminary experiments showed that the inflammation-related cytokines of the pancreatitis were most obvious at the 24 h time-point. Prior to stimulation with CAE for 24 h, the cells were mock pretreated or pretreated with Ang-(1-7) ( $1 \times 10^{-7}$ ,  $1 \times 10^{-6}$  or  $1 \times 10^{-5}$  M; Sigma-Aldrich; Merck KGaA), Ang-(1-7) antagonist A779 ( $1 \times 10^{-7}$ ,  $1 \times 10^{-6}$  or  $1 \times 10^{-5}$  M; Sigma-Aldrich; Merck KGaA),  $1 \times 10^{-5}$  M p38 MAPK inhibitor SB203580 (Beyotime Institute of Biotechnology, Shanghai, China) or  $1 \times 10^{-6}$  M ACE2 inhibitor DX600 (Anaspec Inc., Fremont, CA, USA), respectively, for 30 min. Cells from each group were harvested following the 24 h stimulation with CAE. Cells were then seeded onto glass coverslips in 6-well plates at  $1 \times 10^5$  cells/well for immunocytochemical analysis in triplicates.

**Immunofluorescence assay of ACE2, Mas receptor and p38 MAPK.** In brief, MPC-83 cells were incubated in 4% paraformaldehyde for 40 min at 37°C. Following this fixation step, the cells were blocked with 1% bovine serum albumin (Sigma-Aldrich; Merck KGaA) for 30 min at 37°C. The cells were then incubated with rabbit anti-mouse anti-ACE2 (1:200; ab59351; Abcam, Cambridge, UK) and anti-Mas receptor (1:100; AAR-013; Alomone Labs, Jerusalem, Israel) antibodies at 4°C overnight. The primary antibodies were then incubated for 40 min at 37°C with goat anti-rabbit fluorescein isothiocyanate (FITC) green fluorescent probes (1:100; bs-0295M-FITC; BIOSS, Beijing, China) as the secondary antibody. Cell nuclei were stained with DAPI (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 5 min at 37°C. Immunofluorescence was analyzed by using a fluorescence microscope. Cells incubated with normal rabbit serum (Sigma-Aldrich; Merck KGaA) instead of a primary antibody served as negative control.

**Western blotting of ACE2, Mas receptor, p38 MAPK, phosphorylated (p)-p38 MAPK and NF- $\kappa$ B.** Cells were washed three times with cold phosphate-buffered saline (PBS), followed by lysis on ice with lysis buffer (BIOSS) for 30 min. The total




Figure 1. Representative photomicrographs of untreated MPC-83 cells. (A) Original magnification, x100; (B) original magnification, x200; (C) original magnification, x400. The MPC-83 cells grew into long spindles and adhered to the wall of the culture vessel.

protein concentration was determined using a BCA Protein assay kit (Pierce; Thermo Fisher Scientific, Inc.). Subsequently, 25  $\mu$ g protein-containing lysate sample was separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes, which were then blocked by incubation with 5% non-fat dry milk at 37°C for 2 h. The blocked membranes were incubated with rabbit anti-mouse ACE2 monoclonal antibody (1:400; ab59351), mouse  $\beta$ -actin monoclonal antibody (1:500; ab3280) (both from Abcam, Cambridge, UK), rabbit anti-mouse Mas receptor polyclonal antibody (1:200; AAR-013; Alomone Labs) or rabbit anti-mouse p38 MAPK (1:800), p-p38 MAPK or NF- $\kappa$ B p65 monoclonal antibody (all 1:800; cat. nos. 9212, 4511 and 8242, respectively; Cell Signaling Technology, Inc., Danvers, MA, USA) at 4°C overnight. Subsequent to washing three times with TBST, the membranes were incubated for 1 h at room temperature with horseradish peroxidase (HRP)-conjugated goat anti-rabbit (1:8,000; sc-2004) or goat anti-mouse (1:8,000; sc-2031) secondary antibodies (both from Santa Cruz Biotechnology, Inc.).

Enhanced chemiluminescence HRP substrate (EMD Millipore, Billerica, MA, USA) was used to detect the immune-reactive bands and densitometric analysis of the bands was performed using Image Lab software 3.0 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

**Analysis of p38 MAPK, NF- $\kappa$ B, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-6 (IL-6), IL-8 and IL-10 mRNA expression using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** MPC-83 cells were collected and total RNA was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) in accordance with the manufacturer's protocol. Total RNA (2  $\mu$ g) was subjected to first-strand cDNA synthesis using random primers, M-MLV reverse transcriptase and RNase inhibitor provided in a Revert Aid First Strand cDNA synthesis kit (Fermentas; Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA). The resultant cDNA was subjected to qPCR using specific primers as follows: p38 MAPK forward, 5'-GAGCTGTTGACCGGAAGAAC-3' and reverse, 5'-GGC TTGGCATCCTGTAAATG-3'; NF- $\kappa$ B forward, 5'-CCCGAC TTGTTTGGGTGAT-3' and reverse, 5'-TCCGTCTCCAGG AGGTAA-3'; TNF- $\alpha$  forward, 5'-GGTGCCTATGTCTCA GCCTCTT-3' and reverse, 5'-GCACCTCCACTTGGTGG TTT-3'; IL-6 forward, 5'-AGTTGCCTTCTTGGGACTGA-3' and reverse, 5'-TCCACGATTTCTAGAGAAC-3'; IL-8 forward, 5'-TGAGCTGCGCTGTCAGTGCCT-3' and reverse,

5'-AGAAGCCAGCGTTCACCAGA-3'; IL-10 forward, 5'-ATTTGAATTCCTGGGTGAGAAG-3' and reverse, 5'-CACAGGGGAGAAATCGATGACA-3'; and  $\beta$ -actin forward, 5'-CATCCGTAAAGACCTCTATGCCAAC-3' and reverse, 5'-ATGGAGCCACCGATCCACA-3'. qPCR was performed with a Power SYBR-Green PCR Master mix using an ABI 7500 instrument (both from Applied Biosystems; Thermo Fisher Scientific, Inc.). The qPCR reaction was conducted at 95°C for 5 min, 95°C for 15 sec, and 60°C for 1 min for 40 cycles. Data analysis was performed using the  $2^{-\Delta\Delta C_q}$  method described by Livak and Schmittgen (40).

**Statistical analysis.** All data are presented as mean  $\pm$  standard deviation unless otherwise specified. All experiments were repeated at least three times independently. Results were analyzed using SPSS 13.0 (SPSS, Inc., Chicago, IL, USA), and analysis of variance followed by post hoc analysis using Newman-Keuls tests was used to compare differences among groups.  $P < 0.05$  was considered to indicate a statistically significant difference.

## Results

**Localization of ACE2, Mas receptor and p38 MAPK in MPC-83 cells.** Untreated MPC-83 cells initially cultured in fresh RPMI-1640 media adhered to the walls of the tissue culture flasks at 24 h after incubation. The cells exhibited a long fusiform morphology at a magnification of x100, and the cells appeared to grow well (Fig. 1). Immunofluorescence assays demonstrated that ACE2 and p38 MAPK were present mainly in the cytoplasm, while the Mas receptor was observed mainly in the cell membrane. Furthermore, the expression of ACE2, Mas receptor and p38 MAPK immunofluorescence levels were upregulated in the AP model MPC-83 cells than the control (Fig. 2).

**ACE2, Mas receptor, p38 MAPK, p-p38 MAPK and NF- $\kappa$ B protein levels are upregulated in AP model MPC-83 cells.** Western blot analysis revealed that ACE2 protein levels in the MPC-83 cells were significantly increased ( $P < 0.05$ ) by stimulation with CAE for 2-48 h compared with those in the unstimulated control group. Following exposure to CAE for 24 h, ACE2 expression increased to  $1.16 \pm 0.04$  which was 3-fold greater ( $P < 0.05$ ) than that in the control group ( $0.37 \pm 0.01$ ) (Fig. 3A and B). Mas receptor protein expression peaked following 12 h of AP induction at  $1.22 \pm 0.10$ , which






Figure 2. ACE2, Mas and p38 MAPK localization detected by immunofluorescence. Original magnification, x200. (A) Green staining of target protein using fluorescein isothiocyanate fluorescent probes, (B) blue staining of nuclei using DAPI and (C) merged green and blue staining in MPC-83 cells. ACE2, angiotensin-converting enzyme 2; Mas, receptor for angiotensin-(1-7); p38 MAPK, p38 mitogen-activated protein kinase; CAE, caerulein.

was significantly greater compared with that in the control group ( $0.52 \pm 0.07$ ,  $P < 0.05$ ) (Fig. 3C and D). ACE2 and Mas receptor protein levels were upregulated in the AP model, suggesting that the ACE2-Ang-(1-7)-Mas axis was involved in the pathological process in these cells.

p38 MAPK total proteins contain p-p38 MAPK and unphosphorylated p38 MAPK. In the western blot analysis, p38 MAPK total protein levels in the AP model cells were significantly greater ( $P < 0.05$ ) compared with those in the control group ( $1.07 \pm 0.13$ ) following stimulation with CAE for 24 h ( $1.34 \pm 0.14$ ) and 48 h ( $1.31 \pm 0.13$ ). The p-p38 MAPK levels were significantly higher in the CAE groups compared with the control group ( $0.32 \pm 0.05$ ) for stimulation periods between 2 h ( $0.99 \pm 0.07$ ) and 48 h ( $0.92 \pm 0.14$ ). In addition, the level of p-p38 MAPK peaked ( $1.46 \pm 0.10$ ) at 24 h and then started to decrease (Fig. 3E and F). NF- $\kappa$ B expression underwent a dynamic change during AP, demonstrating a significant elevation. The levels of NF- $\kappa$ B were upregulated ( $P < 0.05$ ) ~2-fold

following 48 h of exposure to CAE ( $1.26 \pm 0.20$ ) compared with the control group ( $0.62 \pm 0.07$ ) (Fig. 3A and B). These results demonstrate that ACE2, Mas receptor protein levels and the p38 MAPK and NF- $\kappa$ B pathway were upregulated during AP.

*Ang-(1-7) upregulates ACE2 and Mas receptor protein but downregulates p38 MAPK, p-p38 MAPK and NF- $\kappa$ B in AP model MPC-83 cells.* Whether Ang-(1-7), a component of the ACE2-Ang-(1-7)-Mas axis, promotes the expression of the axis was investigated using western blot analysis. The results revealed that when AP model MPC-83 cells were treated with different concentrations ( $1 \times 10^{-7}$ ,  $1 \times 10^{-6}$  and  $1 \times 10^{-5}$  M) of Ang-(1-7), the ACE2 and Mas receptor protein levels were significantly increased compared with those in the CAE group, with the exception that ACE2 induction by  $1 \times 10^{-7}$  M Ang-(1-7) was not statistically significant compared with the CAE group. ACE2 and Mas receptor protein expression levels increased from those CAE group as the Ang-(1-7)




Figure 3. Time course of ACE2, Mas, p38 MAPK, p-p38 MAPK and NF- $\kappa$ B protein levels in cultured MPC-83 cells stimulated with CAE for various time periods. (A) Western blotting of ACE2 and NF- $\kappa$ B, and (B) quantified ACE2 and NF- $\kappa$ B protein expression levels. (C) Western blotting of Mas and (D) quantified Mas protein levels. (E) Western blotting of p38 MAPK and p-p38 MAPK and (F) quantified p38 MAPK and p-p38 MAPK protein levels.  $\beta$ -actin was measured in the same gel as an internal standard, the optical density of each band was quantified, and results are presented as the ratio of the target protein to  $\beta$ -actin. \* $P<0.05$  vs. the control group. ACE2, angiotensin-converting enzyme 2; Mas, receptor for angiotensin-(1-7); p38 MAPK, p38 mitogen-activated protein kinase; p-, phosphorylated; NF- $\kappa$ B, nuclear factor- $\kappa$ B; CAE, caerulein.

concentration increased to  $10^{-5}$  M Ang-(1-7) [from  $0.75\pm0.02$  to  $1.12\pm0.01$  and from  $0.56\pm0.04$  to  $0.84\pm0.04$ , respectively ( $P<0.05$ ) (Fig. 4)].

The stimulation of MPC-83 cells with CAE caused a significant increase in p38 MAPK mRNA levels in the CAE group ( $1.41\pm0.23$ ) compared with the control group (Fig. 5A). Similarly, NF- $\kappa$ B mRNA levels increased following stimulation with CAE ( $1.39\pm0.33$ ,  $P<0.050$ ) (Fig. 5B). Conversely, following treatment with Ang-(1-7) at various concentrations ( $1\times10^{-7}$ ,  $1\times10^{-6}$  and  $1\times10^{-5}$  M), an attenuated inflammatory response occurred, as evidenced by decreased p38 MAPK (Fig. 5A) and NF- $\kappa$ B (Fig. 5B) mRNA levels compared with those in the CAE group. In addition, p38 MAPK and p-p38 MAPK protein levels in the AP model MPC-83 cells were inhibited by Ang-(1-7) in a dose-dependent manner [for p38 MAPK  $1\times10^{-6}$  and  $1\times10^{-5}$  M,  $P<0.05$ ) (Fig. 4C and D); for p-p38 MAPK  $1\times10^{-7}$ ,  $1\times10^{-6}$  and  $1\times10^{-5}$  M,  $P<0.05$ ) (Fig. 5C and D)]. Similarly,

NF- $\kappa$ B protein levels were significantly decreased ( $P<0.05$ ) by all three concentrations of Ang-(1-7) compared with those in the CAE group (Fig. 5E and F). Thus, in the MPC-83 cell model of AP, Ang-(1-7) downregulated the p38 MAPK/NF- $\kappa$ B signaling pathway. These results indicate that Ang-(1-7) promoted the expression of the ACE2-Ang-(1-7)-Mas axis and downregulated the p38 MAPK/NF- $\kappa$ B signaling pathway in MPC-83 cells.

*Ang-(1-7) receptor antagonist A779 downregulates Mas without altering ACE2, and upregulates p38 MAPK, p-p38 MAPK and NF- $\kappa$ B levels in AP model MPC-83 cells.* ACE2 levels were increased significantly ( $P<0.05$ ) in the CAE and CAE + A779 groups compared with the control group. However, no significant difference was identified between the groups treated with CAE and CAE + A779 ( $1\times10^{-7}$ ,  $1\times10^{-6}$  and  $1\times10^{-5}$  M) (Fig. 6A and B). The stimulation of MPC-83




Figure 4. Effects of Ang-(1-7) on ACE2, Mas receptor protein and p38 MAPK levels in the control, CAE and CAE + Ang-(1-7) groups of MPC-83 cells as determined by western blotting. (A) Western blotting of ACE2 and (B) quantified ACE2 protein expression levels. (C) Western blotting of Mas and p38 MAPK, and (D) quantified Mas and p38 MAPK protein expression levels. Results are presented as the ratio of the target protein to β-actin. \*P<0.05 vs. the control group; #P<0.05 vs. the CAE group. Ang, angiotensin; ACE2, angiotensin-converting enzyme 2; Mas, receptor for Ang-(1-7); p38 MAPK, p38 mitogen-activated protein kinase; CAE, caerulein.




Figure 5. Effects of Ang-(1-7) on p38 MAPK, p-p38 MAPK and NF-κB levels in the control, CAE and CAE + Ang-(1-7) groups of MPC-83 cells as determined by RT-qPCR and western blotting. Relative quantification of (A) p38 MAPK and (B) NF-κB mRNA expression determined by RT-qPCR. (C) Western blotting of p-p38 MAPK and (D) quantified p-p38 MAPK expression levels. (E) Western blotting of NF-κB and (F) quantified NF-κB expression levels. Quantified western blot results are presented as the ratio of the target protein to β-actin. \*P<0.05 vs. the control group; #P<0.05 vs. the CAE group. Ang, angiotensin; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; p38 MAPK, p38 mitogen-activated protein kinase; p-, phosphorylated; NF-κB, nuclear factor-κB; CAE, caerulein.






Figure 6. Effects of A779 on ACE2 and Mas receptor protein levels in the control, CAE and CAE + A779 groups of MPC-83 cells as determined by western blotting. (A) Western blotting of ACE2 and (B) quantified ACE2 expression levels. (C) Representative western blotting of Mas and (D) quantified Mas expression levels. Results are presented as the ratio of the target protein to  $\beta$ -actin. \* $P < 0.05$  vs. the control group; # $P < 0.05$  vs. the CAE group. A779, Ang-(1-7) antagonist; ACE2, angiotensin-converting enzyme 2; Mas, receptor for Ang-(1-7); Ang, angiotensin; CAE, caerulein.

cells with CAE caused a significant increase in Mas receptor levels in the CAE group ( $0.84 \pm 0.12$ ) compared with the control group ( $0.63 \pm 0.09$ ,  $P < 0.050$ ) (Fig. 6C and D). In the  $1 \times 10^{-5}$  M A779 + CAE group, the Mas receptor expression ( $0.46 \pm 0.05$ ) was significantly decreased ( $P < 0.05$ ) compared with those in the control and CAE groups (Fig. 6C and D).

p38 MAPK and NF- $\kappa$ B mRNA levels were significantly increased following AP induction (to  $1.23 \pm 0.29$  and  $2.60 \pm 1.39$ , respectively;  $P < 0.05$  vs. the control group), and further increased by A779 treatment at different concentrations ( $1 \times 10^{-7}$ ,  $1 \times 10^{-6}$  or  $1 \times 10^{-5}$  M) in a dose-dependent manner (Fig. 7A and B). The changes in p38 and p-p38 MAPK protein levels were comparable with the changes in p38 MAPK and NF- $\kappa$ B mRNA levels (Fig. 7C-F). The NF- $\kappa$ B protein levels were significantly increased ( $P < 0.05$ ) following treatment with  $1 \times 10^{-6}$  or  $1 \times 10^{-5}$  M A779 in comparison with those in the CAE group (Fig. 7G and H).

These results indicate that A779 downregulated the Mas receptor, which downregulated the normal processes associated with the ACE2-Ang-(1-7)-Mas axis, and upregulated p38 MAPK, p-p38 MAPK and NF- $\kappa$ B expression in the MPC-83 cell model of AP. The results further illustrate the association between the ACE2-Ang-(1-7)-Mas axis and the p38 MAPK/NF- $\kappa$ B pathway. However, ACE2 expression was not significantly changed by any of the tested concentrations of A779.

*SB203580 downregulates ACE2, Mas receptor, p-p38 MAPK and NF- $\kappa$ B; conversely, DX600 upregulates p-p38 MAPK and NF- $\kappa$ B in AP model MPC-83 cells.* Western blotting (Fig. 8) revealed that following treatment with SB203580,

an attenuated response to stimulation with CAE occurred, as evidenced by significantly decreased levels of ACE2 in the SB203580 group compared with the CAE group ( $0.16 \pm 0.07$  vs.  $0.28 \pm 0.03$ ) (Fig. 8A and B), Mas receptor ( $0.14 \pm 0.01$  vs.  $0.21 \pm 0.02$ ) (Fig. 8A and D), p-p38 MAPK ( $0.40 \pm 0.12$  vs.  $0.47 \pm 0.01$ ) (Fig. 8C and E) and NF- $\kappa$ B ( $0.66 \pm 0.04$  vs.  $0.76 \pm 0.05$ ) (Fig. 8C and F) compared with those in the CAE group, but no significant effect on p38 MAPK ( $0.66 \pm 0.00$  vs.  $0.65 \pm 0.03$ ) (Fig. 8C and E). By contrast, in the DX600 group, p-p38 MAPK (Fig. 8E) and NF- $\kappa$ B (Fig. 8F) protein levels were significantly increased ( $P < 0.05$ ) compared with those in the CAE group, whereas the protein levels of Mas receptor (Fig. 8A), p38 MAPK (Fig. 8E) underwent no significant changes.

*Ang-(1-7) downregulates the mRNA levels of inflammatory factors IL-6, TNF- $\alpha$  and IL-8, and upregulates IL-10 mRNA levels in AP MPC-83 cells.* The effects of Ang-(1-7) on inflammatory factors were evaluated using the Ang-(1-7) receptor antagonist A779. Following treatment with  $1 \times 10^{-7}$ ,  $1 \times 10^{-6}$  or  $1 \times 10^{-5}$  M Ang-(1-7), the IL-6 mRNA levels were decreased significantly ( $P < 0.05$ ) compared with those in the CAE group (Fig. 9A). In addition, TNF- $\alpha$  and IL-8 mRNA levels were significantly reduced by all concentrations of AngII compared with those in the CAE group; in the  $1 \times 10^{-5}$  M Ang-(1-7) group, the TNF- $\alpha$  levels were reduced from  $0.83 \pm 0.11$  and  $0.68 \pm 0.27$  and the IL-8 levels were reduced from  $0.64 \pm 0.03$  to  $0.43 \pm 0.29$  (both  $P < 0.05$ ) (Fig. 9B and C). Furthermore, following treatment with  $1 \times 10^{-6}$  or  $1 \times 10^{-5}$  M Ang-(1-7), the IL-10 mRNA levels were increased significantly ( $P < 0.05$ ) (Fig. 9D) compared with those in the CAE group.




Figure 7. Effects of A779 on p38 MAPK, p-p38 MAPK and NF-κB mRNA and protein levels in the control, CAE and CAE + Ang-(1-7) groups of MPC-83 cells as determined by RT-qPCR and western blotting. Relative quantification of (A) p38 MAPK and (B) NF-κB mRNA expression by RT-qPCR. (C) Western blotting of p38 MAPK and (D) quantified p38 MAPK expression levels. (E) Western blotting of p-p38 MAPK and (F) quantified p-p38 MAPK expression levels. (G) Western blotting of NF-κB and (H) quantified NF-κB expression levels. Quantified western blot results are presented as the ratio of the target protein to β-actin. \* $P < 0.05$  vs. the control group; \*\* $P < 0.05$  vs. the CAE group. Ang, angiotensin; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; p38 MAPK, p38 mitogen-activated protein kinase; p-, phosphorylated; NF-κB, nuclear factor-κB; CAE, caerulein.

Following stimulation with A779 ( $1 \times 10^{-5}$  M), the IL-6 level of the cells was significantly increased ( $130.26 \pm 35.25$ ) compared with that in the CAE control group ( $P < 0.05$ ) (Fig. 9A). Similarly, the TNF-α levels in the  $1 \times 10^{-6}$  and  $1 \times 10^{-5}$  M A779 groups ( $1.54 \pm 0.09$  and  $7.21 \pm 2.01$ ) was significantly increased compared with that in the CAE group (Fig. 9B). The expression of IL-8 mRNA was increased in a significant and concentra-

tion-dependent manner by A779 (from  $5.50 \pm 1.82$  in the  $1 \times 10^{-7}$  group to  $15.34 \pm 5.57$  in the  $1 \times 10^{-6}$  group) compared with that in the CAE group (Fig. 9C). In addition, following treatment with A779 ( $1 \times 10^{-5}$  M), the IL-10 level was significantly decreased compared with that in the CAE group (Fig. 9D).

IL-6, TNF-α, IL-8 and IL-10 mRNA levels were down-regulated significantly ( $P < 0.05$ ) in the SB203580 group






Figure 8. Effects of SB203580 and DX600 on ACE2, Mas receptor, p38 MAPK, p-p38 MAPK and NF-κB protein levels in the control, CAE, SB203580 and DX600 groups of MPC-83 cells as determined by western blotting. (A) Western blotting of ACE2 and Mas receptor. (B) Quantified expression levels of ACE2. (C) Western blotting of p38 MAPK, p-p38 MAPK and NF-κB. Quantified expression levels of (D) Mas, (E) p38 MAPK, p-p38 MAPK and (F) NF-κB proteins. Results are presented as the ratio of the target protein to β-actin. \*P<0.05 vs. the control group; #P<0.05 vs. the CAE group. Mas, receptor for angiotensin-(1-7); p38 MAPK, p38 mitogen-activated protein kinase; p-, phosphorylated; NF-κB, nuclear factor-κB; CAE, caerulein.




Figure 9. Effects of Ang-(1-7), A779, SB203580 and DX600 on IL-6, TNF-α, IL-8 and IL-10 mRNA levels in MPC-83 cells as determined by reverse transcription-quantitative polymerase chain reaction. Relative quantification of (A) IL-6, (B) TNF-α, (C) IL-8 and (D) IL-10 mRNA expression in the control, CAE, CAE + Ang-(1-7), CAE + A779, SB203580 and DX600 groups. \*P<0.05 vs. the control group; #P<0.05 vs. the CAE group. Ang, angiotensin; A779, Ang-(1-7) antagonist; SB203580, p38 MAPK inhibitor; DX600, ACE2 inhibitor; ACE2, angiotensin-converting enzyme 2; IL, interleukin; TNF, tumor necrosis factor; CAE, caerulein.

compared with the CAE group. By contrast, IL-6, TNF- $\alpha$  and IL-8 mRNA levels were upregulated significantly ( $P < 0.05$ ) in the DX600 group compared with the CAE group. However, there was no significant difference in IL-10 mRNA levels between the CAE and DX600 groups ( $1.40 \pm 0.06$  vs.  $1.39 \pm 0.04$ , respectively;  $P > 0.05$ ). These results indicate that Ang-(1-7) downregulates the inflammatory response in MPC-83 cells, and that A779 functions in opposition to Ang-(1-7).

## Discussion

The present study demonstrates that ACE2 and Mas receptor protein levels are significantly elevated in the MPC-83 cell model of AP, suggesting that the ACE2-Ang-(1-7)-Mas axis is important in protecting acinar cells from inflammation. This was in accordance with previous findings in animal models of pancreatitis, in which the inhibition of the ACE-AngII-AT1 axis significantly decreased pancreatic injury (25,41). Notably, ACE2 congeners have been confirmed to act as RAS antagonists, and the catalytic efficiency of ACE2 in the hydrolysis of AngII to Ang-(1-7) has been demonstrated to be >400-fold greater than that for the hydrolysis of AngI to Ang-(1-9) in the local RAS of the heart and kidneys (42). Previous studies have shown that the binding of Ang-(1-7) to the Mas receptor induces numerous effects, including protection of the vascular endothelium, vasodilation, protection of renal tubular cells and diuresis (43,44), possibly by inhibiting the proliferation and inflammatory reactions occurring in response to hypertensive challenge by AngII. Pancreatic acinar cells synthesize and release cytokines and chemokines, resulting in the recruitment of inflammatory cells, including neutrophils, lymphocytes and macrophages when under oxidative stress or exposed to infection (45). The recruitment and activation of various inflammatory cells lead to further acinar cell injury and cause an elevation of various pro-inflammatory mediators, including TNF- $\alpha$  and IL-6, as well as anti-inflammatory factors such as IL-10 (46,47). The present study demonstrates that exogenous Ang-(1-7) increased ACE2 and Mas receptor expression, but decreased IL-6 and TNF- $\alpha$  mRNA expression in CAE-treated pancreatic acinar cells; further evidence was provided by the application of the Mas receptor antagonist A779. The results suggest that the ACE2-Ang-(1-7)-Mas axis inhibited the production of inflammatory factors and protected MPC-83 cells from damage. However, to the best of our knowledge, the specific signaling pathway through which the ACE2-Ang-(1-7)-Mas axis protects acinar cells from inflammatory injury remains unknown.

In 2004, Ren *et al* (48) demonstrated that p38 MAPK activity in the pancreas was significantly higher than the basal activity 24 h after the induction of SAP, and that the p38 MAPK signal transduction pathway served an important role in the pathogenesis of SAP. In addition, a study has observed that the pancreatic expression of NF- $\kappa$ B increases in rats with acute necrotizing pancreatitis (49). However, the mechanism by which the p38 MAPK and NF- $\kappa$ B signaling pathways are regulated remains unclear. In the present *in vitro* study, p38 MAPK activation was observed in association with the inflammatory response, and p38 MAPK protein levels increased in an approximately time-dependent manner during the AP process, indicating that CAE acts as an environmental stressor and activates the p38 MAPK signaling pathway. In

general cells, mitogen- and stress-activated kinase 1/2, which is a downstream substrate of p38 MAPK, directly phosphorylates and activates transcription factors including NF- $\kappa$ B isoform p65 and histone H3 (49). The involvement of the transcription factor NF- $\kappa$ B in AP has been demonstrated in pancreatic acinar cells, where it induces the release of numerous pro-inflammatory cytokines, including IL-6 and TNF- $\alpha$  (50). In the present study, NF- $\kappa$ B protein levels were observed to increase in a time-dependent manner in the pancreatic acinar cells following stimulation with CAE, indicating that CAE induced an NF- $\kappa$ B-mediated inflammatory response. This is consistent with a previous study of AP in which CAE induced the expression of inhibitor of  $\kappa$ B kinase (IKK) $\alpha$ , phosphorylated IKK $\alpha$  and NF- $\kappa$ B p65, and NF- $\kappa$ B p50 (51). However, the pharmacological inhibition of MAPK during the onset of AP has resulted in mixed outcomes and the role of the p38 MAPK in AP pathogenesis remains controversial. A number of previous studies (52-54) have suggested an adverse effect of NF- $\kappa$ B activation on pancreatitis-associated injury; however, one study (55) proposed a protective role via the induction a self-defending genetic program prior to the onset of pancreatic cellular injury. The present results suggest that MAPK and NF- $\kappa$ B may have harmful functions during the course of AP.

In the present study, the results show that SC203580, a selective inhibitor of p38 MAPK, did not downregulate p38 MAPK expression, whereas, Ang-(1-7) and SB203580 downregulated p-p38 MAPK and NF- $\kappa$ B protein expression, and inflammatory factor (IL-6, TNF- $\alpha$  and IL-8) mRNA expression in AP MPC-83 cells. These results were supported by application of A779 and the ACE2 inhibitor DX600, which exhibited opposite effects. Those results are consistent with previous results from a study of ACE2 knock-out and ACE2 transgenic animals (51). Furthermore, in the present study, Ang-(1-7) upregulated the mRNA level of the anti-inflammatory factor IL-10, while A779 reduced it. These results suggest that the ACE2-Ang-(1-7)-Mas axis contributes to the progression of AP though the p38 MAPK/NF- $\kappa$ B signaling pathway.

The p38 MAPK pathway positively regulates the activity of NF- $\kappa$ B, and p38 MAPK has been shown to affect the activity of IKK and p65 (56). Furthermore, it has been demonstrated that p38 activity is required to enhance the accessibility of the cryptic NF- $\kappa$ B binding sites contained in histone H3 phosphorylated promoters, indicating that p38-dependent H3 phosphorylation may mark promoters for increased NF- $\kappa$ B recruitment (57). In the present study, p38 MAPK, p-p38 MAPK and NF- $\kappa$ B protein levels increased in parallel, indicating that p38 MAPK plays a significant role in the activation of NF- $\kappa$ B signaling in pancreatic cells. Moreover, the present study also found that the expression of ACE2, Mas, NF- $\kappa$ B and pro-inflammatory cytokines was downregulated following the inhibition of p38 MAPK signaling in MPC-83 cells. Accordingly, it may be concluded that the functions of p38 MAPK are mediated by NF- $\kappa$ B signaling in the inflammatory response of pancreatitis, and that p38 MAPK is a key factor in the activation of the ACE2-Ang-(1-7)-Mas axis.

In conclusion, the present study indicates that the ACE2-Ang-(1-7)-Mas axis protects MPC-83 cells from damage via inhibition of the p38 MAPK/NF- $\kappa$ B pathway. Considering the vital role of the ACE2-Ang-(1-7)-Mas axis in the pathogenesis of pancreatitis, substantial efforts to

develop clinical strategies to counter the regulatory axis expression or its activity are recommended, for example, by upregulation of the expression of ACE2 and/or increasing the tissue levels of Ang-(1-7). Understanding the specific interaction of ACE2-Ang-(1-7)-Mas axis components with the p38 MAPK/NF- $\kappa$ B pathway may help in the development of therapeutic agents useful for ameliorating the inflammation reaction and injury of organs in patients with pancreatitis.

### Acknowledgements

The present study was supported by the Beijing Natural Science Foundation of 2014 year (grant no. 7142044) and the National Natural Science Foundation of China of 2016 year (grant no. 81571933). The study was also supported by the National Natural Science Foundation of China (grant no. 81441060).

### References

1. Akay C, Yaman H, Oztosun M, Cakir E, Yildirim AO, Eyi YE, Agilli M, Akgul EO, Aydin I, Kaldirim U, *et al*: The protective effects of taurine on experimental acute pancreatitis in a rat model. *Hum Exp Toxicol* 32: 522-529, 2013.
2. Pan Z, Feng L, Long H, Wang H, Feng J and Chen F: Effects of local pancreatic renin-angiotensin system on the microcirculation of rat with severe acute pancreatitis. *Korean J Physiol Pharmacol* 19: 299-307, 2015.
3. Singh P and Garg PK: Pathophysiological mechanisms in acute pancreatitis: Current understanding. *Indian J Gastroenterol* 35: 153-166, 2016.
4. Singh VK, Wu BU, Bollen TL, Repas K, Maurer R, Mortele KJ and Banks PA: Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. *Clin Gastroenterol Hepatol* 7: 1247-1251, 2009.
5. Mofidi R, Duff MD, Wigmore SJ, Madhavan KK, Garden OJ and Parks RW: Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. *Br J Surg* 93: 738-744, 2006.
6. Liu M, Shi L, Chen M, Chen S and Zou X: Effects of c-Jun N-terminal kinase signaling pathway on severe acute pancreatitis-associated lung injury. *Pancreas* 41: 358-366, 2012.
7. van Santvoort HC, Bakker OJ, Bollen TL, Besselink MG, Ahmed Ali U, Schrijver AM, Boermeester MA, van Goor H, Dejong CH, van Eijck CH, *et al*: Dutch Pancreatitis Study Group: A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. *Gastroenterology* 141: 1254-1263, 2011.
8. Petrov MS, Shanbhag S, Chakraborty M, Phillips AR and Windsor JA: Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. *Gastroenterology* 139: 813-820, 2010.
9. Gul R, Ramdas M, Mandavia CH, Sowers JR and Pulakat L: RAS-mediated adaptive mechanisms in cardiovascular tissues: Confounding factors of RAS blockade therapy and alternative approaches. *Cardiorenal Med* 2: 268-280, 2012.
10. Lenos MG and Tsaniklidou SM: Comment on 'Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice'. *Hepatology* 51: 718, 2010.
11. Verma A, Shan Z, Lei B, Yuan L, Liu X, Nakagawa T, Grant MB, Lewin AS, Hauswirth WW, Raizada MK, *et al*: ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. *Mol Ther* 20: 28-36, 2012.
12. Zhang XP, Li ZJ and Zhang J: Inflammatory mediators and microcirculatory disturbance in acute pancreatitis. *Hepatobiliary Pancreat Dis Int* 8: 351-357, 2009.
13. Ibiş M, Yüksel O, Yilmaz G, Köklü S, Yilmaz FM, Ertugrul I, Uçar E and Altıparmak ME: Serum angiotensin converting enzyme levels in pancreatic diseases. *Hepatogastroenterology* 55: 1814-1817, 2008.
14. Ulmasov B, Xu Z, Talkad V, Oshima K and Neuschwander-Tetri BA: Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. *Am J Physiol Gastrointest Liver Physiol* 299: G70-G80, 2010.
15. Ahmadian E, Pennefather PS, Eftekhari A, Heidari R and Eghbal MA: Role of renin-angiotensin system in liver diseases: An outline on the potential therapeutic points of intervention. *Expert Rev Gastroenterol Hepatol* 10: 1279-1288, 2016.
16. Guo YJ, Li WH, Wu R, Xie Q and Cui LQ: ACE2 overexpression inhibits angiotensin II-induced monocyte chemoattractant protein-1 expression in macrophages. *Arch Med Res* 39: 149-154, 2008.
17. Verdecchia P, Gentile G, Angeli F and Reboli G: Beyond blood pressure: Evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. *Ther Adv Cardiovasc Dis* 6: 81-91, 2012.
18. Fraga-Silva RA, Da Silva DG, Montecucco F, Mach F, Stergiopoulos N, da Silva RF and Santos RA: The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: A potential target for treating thrombotic diseases. *Thromb Haemostasis* 108: 1089-1096, 2012.
19. Santos RA, Ferreira AJ, Verano-Braga T and Bader M: Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: New players of the renin-angiotensin system. *J Endocrinol* 216: R1-R17, 2013.
20. Patel VB, Zhong JC, Grant MB and Oudit GY: Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. *Circ Res* 118: 1313-1326, 2016.
21. Zhang Y, Liu J, Luo JY, Tian XY, Cheang WS, Xu J, Lau CW, Wang L, Wong WT, Wong CM, *et al*: Upregulation of Angiotensin-(1-7)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes. *Antioxid Redox Signal* 23: 880-892, 2015.
22. Márquez-Miranda V, Abrigo J, Rivera JC, Araya-Durán I, Aravena J, Simon F, Pacheco N, González-Nilo FD and Cabello-Verrugio C: The complex of PAMAM-OH dendrimer with Angiotensin-(1-7) prevented the disuse-induced skeletal muscle atrophy in mice. *Int J Nanomedicine* 12: 1985-1999, 2017.
23. Durand MJ, Zinkevich NS, Riedel M, Gutterman DD, Nasci VL, Salato VK, Hijjawi JB, Reuben CF, North PE and Beyer AM: Vascular actions of angiotensin 1-7 in the human microcirculation: Novel role for telomerase. *Arterioscler Thromb Vasc Biol* 36: 1254-1262, 2016.
24. Bihl JC, Zhang C, Zhao Y, Xiao X, Ma X, Chen Y, Chen S, Zhao B and Chen Y: Angiotensin-(1-7) counteracts the effects of Ang II on vascular smooth muscle cells, vascular remodeling and hemorrhagic stroke: Role of the NF $\kappa$ B inflammatory pathway. *Vasc Pharmacol* 73: 115-123, 2015.
25. Oruc N, Ozutemiz O, Nart D, Yuce G, Celik HA and Ilter T: Inhibition of renin-angiotensin system in experimental acute pancreatitis in rats: A new therapeutic target? *Exp Toxicol Pathol* 62: 353-360, 2010.
26. Wang Y, Wang J, Liu R, Qi H, Wen Y, Sun F and Yin C: Severe acute pancreatitis is associated with upregulation of the ACE2-angiotensin-(1-7)-Mas axis and promotes increased circulating angiotensin-(1-7). *Pancreatol* 12: 451-457, 2012.
27. Liu R, Qi H, Wang J, Wang Y, Cui L, Wen Y and Yin C: Angiotensin-converting enzyme (ACE and ACE2) imbalance correlates with the severity of cerulein-induced acute pancreatitis in mice. *Exp Physiol* 99: 651-663, 2014.
28. Liu R, Qi H, Wang J, Wang Y, Cui L, Wen Y and Yin C: Ulinastatin activates the renin-angiotensin system to ameliorate the pathophysiology of severe acute pancreatitis. *J Gastroenterol Hepatol* 29: 1328-1337, 2014.
29. Hemi R, Yochananov Y, Barhod E, Kasher-Meron M, Karasik A, Tirosh A and Kanety H: p38 mitogen-activated protein kinase-dependent transactivation of ErbB receptor family: A novel common mechanism for stress-induced IRS-1 serine phosphorylation and insulin resistance. *Diabetes* 60: 1134-1145, 2011.
30. Gao SC, Yin HB, Liu HX and Sui YH: Research progress on MAPK signal pathway in the pathogenesis of osteoarthritis. *Zhongguo Gu Shang* 27: 441-444, 2014 (In Chinese).
31. Ono K and Han J: The p38 signal transduction pathway: Activation and function. *Cell Signal* 12: 1-13, 2000.
32. Hu H, Zhu X, Lin R, Li Z and Chen L: Suppressive effects of Gua Lou Gui Zhi decoction on MCAO-induced NO and PGE2 production are dependent on the MAPK and NF- $\kappa$ B signaling pathways. *Mol Med Rep* 14: 5141-5147, 2016.
33. Moreno JA, Sullivan KA, Carbone DL, Hanneman WH and Tjalkens RB: Manganese potentiates nuclear factor-kappaB-dependent expression of nitric oxide synthase 2 in astrocytes by activating soluble guanylate cyclase and extracellular responsive kinase signaling pathways. *J Neurosci Res* 86: 2028-2038, 2008.
34. Carter AB and Hunninghake GW: A constitutive active MEK-ERK pathway negatively regulates NF-kappa B-dependent gene expression by modulating TATA-binding protein phosphorylation. *J Biol Chem* 275: 27858-27864, 2000.



35. Williard DE, Twait E, Yuan Z, Carter AB and Samuel I: Nuclear factor kappa B-dependent gene transcription in cholecystokinin- and tumor necrosis factor-alpha-stimulated isolated acinar cells is regulated by p38 mitogen-activated protein kinase. *Am J Surg* 200; 283-290, 2010.
36. Twait E, Williard DE and Samuel I: Dominant negative p38 mitogen-activated protein kinase expression inhibits NF-kappaB activation in AR42J cells. *Pancreatol* 10: 119-128, 2010.
37. Yu JH, Lim JW and Kim H: Altered gene expression in cerulein-stimulated pancreatic acinar cells: Pathologic mechanism of acute pancreatitis. *Korean J Physiol Pharmacol* 13: 409-416, 2009.
38. Rolny P, Arleback A, Funch-Jensen P, Kruse A, Ravnsbaeck J and Järnerot G: Paradoxical response of sphincter of Oddi to intravenous injection of cholecystokinin or ceruletide. Manometric findings and results of treatment in biliary dyskinesia. *Gut* 27: 1507-1511, 1986.
39. Cui L, Liu R, Li C, Yu X, Liu X, Hou F, Chi C, Yin C and Wang C: Angiotensin (1-7) attenuates cerulein induced pancreatic acinar cell apoptosis. *Mol Med Rep* 16: 3455-3460, 2017.
40. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
41. Tsang SW, Ip SP and Leung PS: Prophylactic and therapeutic treatments with AT 1 and AT 2 receptor antagonists and their effects on changes in the severity of pancreatitis. *Int J Biochem Cell Biol* 36: 330-339, 2004.
42. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, *et al*: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem* 277: 14838-14843, 2002.
43. Ren T, He H, Yu X, Fan J, Tan J and Liu J: Angiotensin-(1-7) inhibits hypoxia-induced renal tubular epithelial-to-mesenchymal transition in rats. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi* 29: 593-596, 2013 (In Chinese).
44. Su Z, Zimpelmann J and Burns KD: Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. *Kidney Int* 69: 2212-2218, 2006.
45. Pérez S, Pereda J, Sabater L and Sastre J: Redox signaling in acute pancreatitis. *Redox Biol* 5: 1-14, 2015.
46. Lee WS, Shin JS, Jang DS and Lee KT: Cnidilide, an alkylphthalide isolated from the roots of *Cnidium officinale*, suppresses LPS-induced NO, PGE2, IL-1 $\beta$ , IL-6 and TNF- $\alpha$  production by AP-1 and NF- $\kappa$ B inactivation in RAW 264.7 macrophages. *Int Immunopharmacol* 40: 146-155, 2016.
47. Makhija R and Kingsnorth AN: Cytokine storm in acute pancreatitis. *J Hepatobiliary Pancreat Surg* 9: 401-410, 2002.
48. Ren HB, Li ZS, Xu GM, Tu ZX, Shi XG, Jia YT and Gong YF: Dynamic changes of mitogen-activated protein kinase signal transduction in rats with severe acute pancreatitis. *Chin J Dig Dis* 5: 123-125, 2004.
49. Xu M, Wang KN, Wu K and Wang XP: Pyrrolidine dithiocarbamate inhibits nuclear factor  $\kappa$ B and Toll-like receptor 4 expression in rats with acute necrotizing pancreatitis. *Gut Liver* 9: 411-416, 2015.
50. Vaquero E, Gukovsky I, Zaninovic V, Gukovskaya AS and Pandol SJ: Localized pancreatic NF-kappaB activation and inflammatory response in taurocholate-induced pancreatitis. *Am J Physiol Gastrointest Liver Physiol* 280: G1197-G1208, 2001.
51. Bettaieb A, Xi Y, Hosein E, Coggins N, Bachaalany S, Wiede F, Perez S, Griffey SM, Sastre J, Tiganis T, *et al*: Pancreatic T cell protein-tyrosine phosphatase deficiency ameliorates cerulein-induced acute pancreatitis. *Cell Commun Signal* 12: 13, 2014.
52. Li G, Wu X, Yang L, He Y, Liu Y, Jin X and Yuan H: [Corrigendum] TLR4-mediated NF- $\kappa$ B signaling pathway mediates HMGB1-induced pancreatic injury in mice with severe acute pancreatitis. *Int J Mol Med* 38: 1313, 2016.
53. Shi Q, Liao KS, Zhao KL, Wang WX, Zuo T, Deng WH, Chen C, Yu J, Guo WY, He XB, *et al*: Hydrogen-rich saline attenuates acute renal injury in sodium taurocholate-induced severe acute pancreatitis by inhibiting ROS and NF- $\kappa$ B pathway. *Mediators Inflamm* 2015: 685043, 2015.
54. Yang X, Jin H, Liu K, Gu Q and Xu X: A novel peptide derived from human pancreatitis-associated protein inhibits inflammation in vivo and in vitro and blocks NF-kappa B signaling pathway. *PLoS One* 6: e29155, 2011.
55. Steinle AU, Weidenbach H, Wagner M, Adler G and Schmid RM: NF-kappaB/Rel activation in cerulein pancreatitis. *Gastroenterology* 116: 420-430, 1999.
56. Kefaloyianni E, Gaitanaki C and Beis I: ERK1/2 and p38-MAPK signalling pathways, through MSK1, are involved in NF-kappaB transactivation during oxidative stress in skeletal myoblasts. *Cell Signal* 18: 2238-2251, 2006.
57. Saccani S, Pantano S and Natoli G: p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. *Nat Immunol* 3: 69-75, 2002.